Abstract 5635
Background
A cancer diagnosis often causes an emotional impact with signs of anxiety, uncertainty and subjective discomfort. It´s necessary to identify and assess emotional discomfort to offer quality treatment articulated around the patient and his / her demand. The design of a questionnaire that is easy to use and understand, allows the detection of patients susceptible to referral to the Psycho-oncology Unit (POU).
Methods
- Prepare a PAQ that includes: Evaluation of emotional distress assisted by visual analogue scales (VAS); Modified Gijón scale (sociofamilar assessment scale); previous use of psychoactive drugs - Include PAQ in the first nursing visit - Quick referral to POU - Interview with psycho-oncology nurse - Valuation, diagnosis and treatment planning by POU - Data recording - Data analysis.
Results
Patients with a positive PAQ are referred to the POU where the liaison nurse performs an interview with the patient and / or family. The nurse collects data on psychobiography, oncological disease, psychic sphere, frequent affections, previous contacts with psychologists / psychiatrists and treatments with psychoactive drugs. The POU will offer the patient the most appropriate resource for their needs (Psychotherapy, Psychopharmaceuticals, and Social Work Service).
Conclusions
The inclusion of the PAQ in the first visit of nursing allows the detection and early treatment of disorders in the psychosocial area. We achieve an optimal use of resources, a greater adherence to the proposed oncological treatment, alleviate problems that are found throughout the oncological treatment and improve the quality of life of our patients by reducing emotional discomfort.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2171 - CCND1 Amplification Contributes to Immunosuppression in Head and Neck Squamous Cell Carcinoma and the Association with a Poor Response to Immune Checkpoint Inhibitors
Presenter: Chloe Huang
Session: Poster Display session 3
Resources:
Abstract
2624 - Efficacy of PD-1/PD-L1 inhibitors in the treatment of non-small cell lung cancer patients with sensitive genes mutation
Presenter: Hui-Juan Cui
Session: Poster Display session 3
Resources:
Abstract
3494 - Neutrophil to Lymphocyte Ratio (NLR) kinetics as predictors of outcomes in metastatic renal cell carcinoma (mRCC) and non-small cell lung cancer (NSCLC) patients treated with nivolumab (N).
Presenter: Audrey Simonaggio
Session: Poster Display session 3
Resources:
Abstract
3964 - Predictive markers of checkpoint inhibitor activity in adult metastatic solid tumours
Presenter: Alexandra Pender
Session: Poster Display session 3
Resources:
Abstract
3041 - Blood-based TMB (bTMB) correlates with tissue-based TMB (tTMB) in a multi-cancer Phase I IO Cohort
Presenter: Daniel Araujo
Session: Poster Display session 3
Resources:
Abstract
3910 - Analysis of Molecular Profile Complexities for Immunotherapy Decision Support
Presenter: Robert Dóczi
Session: Poster Display session 3
Resources:
Abstract
4836 - The Role of Tumor Neoantigens in the Differential Response to Immunotherapy (IO) in EGFR and BRAF Mutated Lung Cancers - Quantity or Quality?
Presenter: Katrina Case
Session: Poster Display session 3
Resources:
Abstract
1929 - Impact of previous corticosteroid (CS) exposure on efficacy of Programmed Cell Death-(Ligand) 1 blockade in patients with advanced Non-Small-Cell Lung Cancer (NSCLC): a single Center retrospective analysis
Presenter: Fabrizio Nelli
Session: Poster Display session 3
Resources:
Abstract
2601 - Comparison 18F-FDG-PET/CT criteria for prediction of therapy response and clinical outcome in patients with metastatic melanoma treated with Ipilimumab and PD-1 inhibitors
Presenter: Sabrina Vari
Session: Poster Display session 3
Resources:
Abstract
3628 - Predictive model for survival in advanced non-small-cell lung cancer (NSCLC) treated with frontline pembrolizumab
Presenter: Xabier Mielgo Rubio
Session: Poster Display session 3
Resources:
Abstract